Novo Nordisk Pays Out DKK 15 Million in NAION Claims While NovoCare and CagriSema Shape the Wegovy Story
Published on 11/20/2026 at 03:20 | Editorial boerse-global.deDenmark's patient compensation body has awarded a total of DKK 15 million to 31 people who developed the rare eye condition NAION after using Novo Nordisk's Wegovy or Ozempic, with the Danish state footing the bill. The agency received 94 applications in all, rejected 29 and has 34 still pending. Novo Nordisk maintains there is no causal link between its medicines and the eye disorder.
The payout lands against a widening regulatory backdrop. On 9 November, according to Reuters, the US Food and Drug Administration asked for a warning on GLP-1 drugs including Wegovy and Ozempic flagging a possibly increased risk of NAION, which can cause sudden vision loss. That is a medical question Novo Nordisk's commercial initiatives cannot answer.
NovoCare Reboot Targets the Daily Grind of Treatment
Novo Nordisk on Tuesday relaunched NovoCare, its support programme for Wegovy users. The bundle pulls together information on treatment and insurance coverage with home delivery, coaching and partner offers, and a points scheme is in the works. Each piece addresses a different obstacle: guidance helps with orientation, delivery simplifies refills, coaching accompanies day-to-day use.
For investors, the test is not how many people visit the programme but whether more patients stay on Wegovy. A coverage inquiry is not the same as a commitment to pay. NovoCare therefore demands a different kind of proof than a new drug — evidence that the services actually dismantle practical hurdles. Clinical data on Novo Nordisk's other products cannot settle that question, however important it is for the wider pipeline.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
In the best case the pieces interlock. Patients resolve coverage questions more easily and use home delivery to keep supplies coming, and if that prevents interruptions, NovoCare could buttress Wegovy without any change to the medicine itself. In the worst case, patients absorb the extra information while their ability to continue treatment stays the same; if coverage remains the sticking point, convenient delivery and coaching may bypass it entirely. The planned points programme is the next announced building block, and its launch alone would be an expansion of the offering rather than proof of an effect.
Pipeline News Piles Up
Novo Nordisk shares slipped 2.0% on Thursday evening and are down 4.2% over seven days.
On the development front, the European Commission granted marketing authorisation for Frehemgo on 13 November. The drug is used in adults and children with haemophilia A, with or without inhibitors, to prevent or reduce bleeding on a regular basis, and can be given monthly, every two weeks or weekly.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
That same day Novo Nordisk said it had filed for approval of Etavopivat for adolescents and adults with sickle cell disease with both the FDA and the EMA, expecting decisions from the two agencies in 2027.
For CagriSema, still in development, the company reported results from the Phase 3 REDEFINE 9 trial on 14 November. After 68 weeks, estimated mean weight loss on the two lower dosing regimens came to 20.7% and 21.0%, against 2.0% on placebo. Those estimates assume participants kept up their treatment. The distinction matters for investors: NovoCare targets the everyday routine of taking Wegovy, while the CagriSema study probes how further dosing schedules perform.
Ad
Novo Nordisk Stock: New Analysis - 20 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
